These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37083603)

  • 1. Prevalence of Buprenorphine Providers Requiring Cash Payment From Insured Women Seeking Opioid Use Disorder Treatment.
    Richards MR; Leech AA; Stein BD; Buntin MB; Patrick SW
    Med Care; 2023 Jun; 61(6):377-383. PubMed ID: 37083603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
    Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
    Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder.
    Patrick SW; Richards MR; Dupont WD; McNeer E; Buntin MB; Martin PR; Davis MM; Davis CS; Hartmann KE; Leech AA; Lovell KS; Stein BD; Cooper WO
    JAMA Netw Open; 2020 Aug; 3(8):e2013456. PubMed ID: 32797175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicaid prevalence and opioid use disorder treatment access disparities.
    Richards MR; Leech AA; Stein BD; Buntin MB; Patrick SW
    Health Serv Res; 2022 Apr; 57(2):422-429. PubMed ID: 34862609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproductive-Age Women's Experience of Accessing Treatment for Opioid Use Disorder: "We Don't Do That Here".
    Phillippi JC; Schulte R; Bonnet K; Schlundt DD; Cooper WO; Martin PR; Kozhimannil KB; Patrick SW
    Womens Health Issues; 2021; 31(5):455-461. PubMed ID: 34090780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment access for opioid use disorder among women with medicaid in Florida.
    Elmore AL; Patrick SW; McNeer E; Fryer K; Reid CN; Sappenfield WM; Mehra S; Salemi JL; Marshall J
    Drug Alcohol Depend; 2023 May; 246():109854. PubMed ID: 37001322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. County-level Factors and Treatment Access Among Insured Women With Opioid Use Disorder.
    Leech AA; McNeer E; Stein BD; Richards MR; McElroy T; Dupont WD; Patrick SW
    Med Care; 2023 Dec; 61(12):816-821. PubMed ID: 37199507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018.
    Schuler MS; Saloner B; Gordon AJ; Dick AW; Stein BD
    Subst Abus; 2023 Jul; 44(3):154-163. PubMed ID: 37278310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Primary Care in the Initiation of Opioid Use Disorder Treatment in Statewide Public and Private Insurance.
    Gertner AK; Rotter JS; Holly ME; Shea CM; Green SL; Domino ME
    J Addict Med; 2022 Mar-Apr 01; 16(2):183-191. PubMed ID: 33973922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
    JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
    Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
    J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.
    Cole ES; DiDomenico E; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kim JY; Kmiec J; Kelley D; Donohue JM
    J Gen Intern Med; 2019 Jun; 34(6):936-943. PubMed ID: 30887440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings.
    Choi S; Healy S; Shapoval L; Forthal S; Neighbors CJ
    Subst Use Misuse; 2021; 56(2):258-263. PubMed ID: 33345680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.